Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM2 | P50570 | 8/20 | 0.78 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.61 |
| ▸ | MERTK | Q12866 | 1/20 | 0.57 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.53 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.47 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.47 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.47 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19477219 | 0.95 | DNM2 (0.71) | DNM2TLR8MERTKMAPK8HRH4 | |
| SCHEMBL11280972 | 0.91 | DNM2 (0.71) | DNM2TLR8MERTKMAPK8HRH4 | |
| SCHEMBL11289519 | 0.91 | DNM2 (0.71) | DNM2TLR8MERTKMAPK8HRH4 | |
| SCHEMBL19477222 | 0.87 | TLR8 (0.63) | DNM2TLR8MERTKMAPK8HRH4 | |
| SCHEMBL19476564 | 0.87 | TLR8 (0.63) | DNM2TLR8MERTKMAPK8HRH4 | |
| SCHEMBL19462384 | 0.85 | DNM2 (0.59) | DNM2TLR8MERTKMAPK8HRH4 | |
| SCHEMBL2574691 | 0.85 | DNM2 (0.59) | DNM2TLR8MERTKMAPK8HRH4 | |
| SCHEMBL2947094 | 0.85 | DNM2 (0.90) | DNM2TLR8MERTKMAPK8HRH4 | |
| SCHEMBL19477221 | 0.85 | DNM2 (0.80) | DNM2TLR8MERTKMAPK8HRH4 | |
| SCHEMBL19476566 | 0.85 | DNM2 (0.80) | DNM2TLR8MERTKMAPK8HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114805301-B | 2, 4-diaryl aminopyrimidine compound and preparation method and application thereof | 沈阳药科大学 | 2024-04-05 | — | — | CN | claimed |
| CN-116003331-A | 2, 4-diarylaminopyrimidine derivative and application thereof | 浙江工业大学 | 2023-04-25 | — | — | CN | claimed |
| CN-110218205-B | 2, 4-diarylaminopyrimidine derivatives containing pyridine structure and application thereof | 辽宁大学 | 2022-04-05 | — | — | CN | claimed |
| CN-111484484-B | 2, 4-diaryl aminopyrimidine derivative containing aromatic heterocycle and preparation and application thereof | 沈阳药科大学 | 2021-11-23 | — | — | CN | claimed |
| CN-111484484-A | 2, 4-diaryl aminopyrimidine derivative containing aromatic heterocycle and preparation and application thereof | 沈阳药科大学 | 2020-08-04 | — | — | CN | claimed |
| CN-114805301-B | 2, 4-diaryl aminopyrimidine compound and preparation method and application thereof | 沈阳药科大学 | 2024-04-05 | — | — | CN | disclosed |
| CN-114805301-B | 2, 4-diaryl aminopyrimidine compound and preparation method and application thereof | 沈阳药科大学 | 2024-04-05 | — | — | CN | disclosed |
| CN-116003331-A | 2, 4-diarylaminopyrimidine derivative and application thereof | 浙江工业大学 | 2023-04-25 | — | — | CN | disclosed |
| CN-116003331-A | 2, 4-diarylaminopyrimidine derivative and application thereof | 浙江工业大学 | 2023-04-25 | — | — | CN | disclosed |
| CN-114805301-A | 2, 4-diarylaminopyrimidine compounds and preparation method and application thereof | 沈阳药科大学 | 2022-07-29 | — | — | CN | disclosed |
| CN-114805301-A | 2, 4-diarylaminopyrimidine compounds and preparation method and application thereof | 沈阳药科大学 | 2022-07-29 | — | — | CN | disclosed |
| CN-114805301-A | 2, 4-diarylaminopyrimidine compounds and preparation method and application thereof | 沈阳药科大学 | 2022-07-29 | — | — | CN | disclosed |
| EP-0945443-B1 | HIV inhibiting pyrimidine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2003-02-12 | — | — | EP | disclosed |
| EP-1245567-A1 | HIV inhibiting pyrimidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-10-02 | — | — | EP | disclosed |
| US-6440986-B2 | VIRICIDES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2002-08-27 | — | — | US | disclosed |
| US-20010011094-A1 | HIV inhibiting pyrimidine derivatives | ANDRIES KOENRAAD JOZEF LODEWIJ (BE) | 2001-08-02 | — | — | US | disclosed |
| US-6197779-B1 | VIRICIDE | JANSSEN PHARMACEUTICA, INC. | 2001-03-06 | — | — | US | disclosed |
| WO-1999050250-A1 | HIV INHIBITING PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-10-07 | — | — | WO | disclosed |
| EP-0945443-A1 | HIV inhibiting pyrimidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-09-29 | — | — | EP | disclosed |
| EP-0945442-A1 | Trisubstituted pyrimidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010011094-A1 | HIV inhibiting pyrimidine derivatives | CBR1, CCR1, NR4A1 | DNM2 2499/4885TLR8 2119/4885MERTK 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.